Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives
AbstractCarcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”, “angiogenesis therapy”, “cancer stem cell therapy”, “prognostic biomarker”, and “novel antibody-drug”. Based on our results, the differential expression and accessibility of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells in comparison to normal tissues and Human Epidermal Growth Factor Receptor 2 (HER2) open up new possibilities in the field of target therapy. Nevertheless, future investigations are needed to clarify the impact of these new therapies on survival rate and medium-/long-term outcomes. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Vitale, S.G.; Laganà, A.S.; Capriglione, S.; Angioli, R.; La Rosa, V.L.; Lopez, S.; Valenti, G.; Sapia, F.; Sarpietro, G.; Butticè, S.; Tuscano, C.; Fanale, D.; Tropea, A.; Rossetti, D. Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. Int. J. Mol. Sci. 2017, 18, 1100.
Vitale SG, Laganà AS, Capriglione S, Angioli R, La Rosa VL, Lopez S, Valenti G, Sapia F, Sarpietro G, Butticè S, Tuscano C, Fanale D, Tropea A, Rossetti D. Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. International Journal of Molecular Sciences. 2017; 18(5):1100.Chicago/Turabian Style
Vitale, Salvatore G.; Laganà, Antonio S.; Capriglione, Stella; Angioli, Roberto; La Rosa, Valentina L.; Lopez, Salvatore; Valenti, Gaetano; Sapia, Fabrizio; Sarpietro, Giuseppe; Butticè, Salvatore; Tuscano, Carmelo; Fanale, Daniele; Tropea, Alessandro; Rossetti, Diego. 2017. "Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives." Int. J. Mol. Sci. 18, no. 5: 1100.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.